All In Biotech

Drug Trial Radar · NCT07672561

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Nov 30, 2026

Study completion Jul 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • Drug:WD-890Drug

    WD-890 tablet will be administered orally.

  • Drug: placeboDrug

    Placebo tablet will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Weeks 16Time frame: Screening up to Week 16
  2. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16Time frame: Screening up to Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of Dermatology, Chinese Academy of Medical Sciences

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.